Empagliflozin Under Review for Patients With Chronic Kidney Disease
The FDA has accepted the sNDA for empagliflozin to reduce the risk of kidney disease progression and CV death in adults with chronic kidney disease.
Source: empr.com
Page 4 - Mohamed Eid News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Mohamed Eid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Mohamed Eid Today - Breaking & Trending Today
Third edition of Build Your House Exhibition continues to provide inspiration, practical advice
Doha: The second day of Build Your House (BYH) Exhibition 2022 welcomed a fantastic number of visitors, exhibitors, speakers, and saw the awarding of...
Source: thepeninsulaqatar.com
BYH expo offers inspiration, practical advice to participants
Build Your House (BYH) Exhibition 2022 continues to serve as a platform that seeks to stimulate the real estate and construction sectors by gathering leading
Source: gulf-times.com
Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease
The Independent Data Monitoring Committee recommended that the EMPA-KIDNEY trial be stopped early, following a formal interim assessmentEMPA-KIDNE...
Source: businessinsider.com
Clinical Benefit Seen With In-Hospital Initiation of Empagliflozin in Heart Failure Patients
Treatment with empagliflozin was shown to improve clinical outcomes in adults hospitalized for acute heart failure when initiated after stabilization and prior to discharge.
Source: endocrinologyadvisor.com